Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6441)
All Articles published online
|
Publishing Process of This Article
|
Jun 15, 2014 (publication date) through Oct 31, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bhatia J, Gamad N, Bharti S, Arya DS. Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J Diabetes 2014; 5(3): 399-406 [PMID: 24936262 DOI: 10.4239/wjd.v5.i3.399] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v5/i3/399.htm |
| Number | Citing Articles |
| 1 |
Hayder Ridha-Salman, Adeeb Ahmed Al-Zubaidy, Alaa Hamza Abbas, Dhuha M Hassan, Samir A Malik. The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; doi: 10.1007/s00210-024-03406-y
|
| 2 |
Saori Yonekubo, Satoshi Tatemichi, Kazuyasu Maruyama, Mamoru Kobayashi. Alpha1A-adrenoceptor antagonist improves underactive bladder associated with diabetic cystopathy via bladder blood flow in rats. BMC Urology 2017; 17(1) doi: 10.1186/s12894-017-0256-9
|
| 3 |
SooJeong Ko, HyungMin Kim, Jiwon Shinn, Sun‐ju Byeon, Jeong‐Hee Choi, Hun‐Sung Kim. Estimation of sodium‐glucose cotransporter 2 inhibitor–related genital and urinary tract infections via electronic medical record–based common data model. Journal of Clinical Pharmacy and Therapeutics 2021; 46(4): 975 doi: 10.1111/jcpt.13381
|
| 4 |
Grzegorz Mizerski, Pawel Kicinski, Andrzej Jaroszynski. Flozins, inhibitors of type 2 renal sodium-glucose co-transporter – not only antihyperglycemic drugs. Current Issues in Pharmacy and Medical Sciences 2015; 28(3): 155 doi: 10.1515/cipms-2015-0063
|
| 5 |
Tushar Madaan, Mohd. Akhtar, Abul Kalam Najmi. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences 2016; 93: 244 doi: 10.1016/j.ejps.2016.08.025
|
| 6 |
A. Pozzi, C. Cirelli, A. Merlo, F. Rea, C. Scangiuzzi, E. Tavano, A. Iorio, S. L. Kristensen, C. Wong, A. Iacovoni, G. Corrado. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews 2023; 29(1): 207 doi: 10.1007/s10741-023-10363-w
|
| 7 |
Grabner Michael, Peng Xiaomei, Caroline Geremakis, Jay Bae. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Journal of Managed Care & Specialty Pharmacy 2015; 21(12): 1204 doi: 10.18553/jmcp.2015.21.12.1204
|
| 8 |
Nadia M.S. Arafa, Mohamed-Assem S. Marie, Sara Abdullah Mubarak AlAzimi. Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model. Chemico-Biological Interactions 2016; 258: 79 doi: 10.1016/j.cbi.2016.08.016
|
| 9 |
S. Halimi, B. Vergès. Adverse effects and safety of SGLT-2 inhibitors. Diabetes & Metabolism 2014; 40(6): S28 doi: 10.1016/S1262-3636(14)72693-X
|
| 10 |
Alexander Kuhn, Jean Park, Adline Ghazi, Vanita R. Aroda. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports 2017; 19(3) doi: 10.1007/s11886-017-0832-3
|